Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

75.70 +0.17 (+0.23%)
Streaming Delayed Price Updated: 2:43 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,271,850
Open 75.67
Bid (Size) 75.68 (3)
Ask (Size) 75.69 (5)
Prev. Close 75.53
Today's Range 75.14 - 76.06
52wk Range 61.45 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Gilead Sciences Inc. (NASDAQ: GILD) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
Exposures COVID-19

Performance

YTD
-11.35%
-11.35%
1 Month
-1.74%
-1.74%
3 Month
-0.41%
-0.41%
6 Month
-6.51%
-6.51%
1 Year
+21.43%
+21.43%

More News

Read More
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Gilead Sciences Unusual Options Activity
Via Benzinga
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
From Gilead Sciences, Inc.
Via Business Wire
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
Via Benzinga
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Via The Motley Fool
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
Via MarketBeat
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
Via FinancialNewsMedia
Exposures Product Safety
Where Gilead Sciences Stands With Analysts
Via Benzinga
Time For Gilead Sciences-Heavy ETFs?
Via Talk Markets
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
Via Benzinga
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
What You Need to Know About Hepatitis C This Recovery Month
Via Brandpoint
Exposures COVID-19
How To Earn $500 A Month From Gilead Sciences Stock
Via Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
Via Benzinga
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
Via Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Gilead Prices $2 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.